Ganaxolone not checked

Immedica Pharma AB

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
1 active
1 in total

What this is

How it works
Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator FDA class
Tested for
CDKL5 Deficiency Disorder
Main trialPhase 3
“The goal of this clinical trial is to learn how patients with CDKL-5 deficiency disorder (CDD) aged 6 months to 2 years of age respond to treatment with ganaxolone. The main questions the trial aims to answer are: * The amount of the medicine that was in participants' bodies and the safety of the medicine. * Does the medicine ganaxolone lower the number of seizures when used in addition to the participant's usual anti-seizure treatment. Participants will: Take ganaxolone 3 times daily for up to 52 weeks. Visit the clinic every 3 to 5 weeks for the initial 17 weeks of the trial and…”In the company’s words, NCT05249556 on ClinicalTrials.gov
Other names
Ztalmy · Active Drug

Other drugs for CDKL5 Deficiency Disorder

All 2 drugs for CDKL5 Deficiency Disorder

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 3Not yet recruiting Dec 2029 Open-label, Single-arm Trial of Ganaxolone in CDD Patients 6 Months to Less Than 2 Years Old
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Ganaxolone

Following is part of Solo: you see every change to Ganaxolone the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in